DCAF13 Drives Liver Cancer Growth by Tagging RCAN1.4 for Destruction

In a study published in Biology Direct on 24 October 2026, researchers report that DCAF13 is markedly elevated in liver tumor tissues and in hepatocellular carcinoma cell lines, and that patients whose tumors show high DCAF13 expression tend to have more advanced disease and poorer overall survival.

The study, led by Fangzhe Tan, Xiongwen Shi, Hongxin Lang and Xiaohang Li, focused on a long-standing question in cancer biology: how abnormalities in the ubiquitin proteasome system, the cellular machinery that tags proteins for destruction, contribute to tumor progression. DCAF13, short for DDB1 and CUL4 associated factor 13, functions as a substrate receptor for the CRL4 E3 ubiquitin ligase, meaning it helps decide which proteins the ligase marks with ubiquitin. Which proteins DCAF13 targets in liver cancer, and what consequences that has, had not been fully worked out.

To probe DCAF13’s function, the team reduced its levels in hepatocellular carcinoma cells in the laboratory. The effects were striking: with DCAF13 knocked down, the cells proliferated more slowly, formed fewer colonies, and migrated less aggressively. The cells also underwent more apoptosis, the programmed cell death process that cancer cells often evade. In animal models, reducing DCAF13 similarly suppressed tumor growth, suggesting the protein supports malignancy not only in culture but in living tissue.

The researchers then turned to RNA sequencing to identify the molecular pathways DCAF13 influences. The analysis revealed that DCAF13 positively regulates the calcium signaling pathway. That finding pointed the investigators toward a specific downstream mechanism connecting a ubiquitin ligase adaptor to calcium-dependent signaling in cancer cells.

At the heart of that mechanism sits RCAN1.4, a protein the team showed DCAF13 binds directly. According to the study, DCAF13 promotes the ubiquitination of RCAN1.4, which sends the protein to the proteasome for degradation. RCAN1.4 normally acts as a brake on calcineurin, a calcium-activated enzyme. When DCAF13 drives RCAN1.4 levels down, that brake weakens, and calcineurin activity rises. The consequence, the researchers report, is an accumulation of NFAT1, a transcription factor, in the cell nucleus.

In other words, the study outlines a chain of events: DCAF13 tags RCAN1.4 for destruction, RCAN1.4’s inhibition of calcineurin is lifted, and NFAT1 accumulates in the nucleus, all of which the authors link to the calcium signaling changes they observed and to the aggressive cellular behaviors seen when DCAF13 is abundant. The work is presented as a mechanistic study conducted in cell lines and animal models, and its conclusions about how the pathway operates in patients will require further investigation.

The findings carry potential clinical implications. Because DCAF13 expression correlated with advanced TNM stage and poor overall survival in the tumors examined, the authors suggest it could serve as a biomarker, a measurable indicator that helps characterize a patient’s disease. They also propose DCAF13 as a potential therapeutic target, though the study itself did not test any drug or treatment, and developing a therapy against a ubiquitin ligase substrate receptor would require substantial additional research.

The article was published as an open-access paper under Biology Direct’s early-release process, which shares peer-reviewed, accepted research quickly; the published version is subject to further edits before the final Version of Record replaces it. For now, the study adds a specific molecular link, DCAF13, RCAN1.4, calcineurin and NFAT1, to the growing map of ubiquitin system alterations in liver cancer, and offers researchers a defined pathway to explore as they search for new ways to slow hepatocellular carcinoma’s progression.

Subject of Research: The role of DCAF13-mediated RCAN1.4 ubiquitination in hepatocellular carcinoma progression

Article Title: DCAF13 promotes hepatocellular carcinoma progression by mediating RCAN1.4 ubiquitination and activating calcineurin/NFAT1 signaling

Article References: Tan, F., Shi, X., Lang, H., & Li, X. (2026). DCAF13 promotes hepatocellular carcinoma progression by mediating RCAN1.4 ubiquitination and activating calcineurin/NFAT1 signaling. Biology Direct. https://doi.org/10.1186/s13062-026-01034-5

Image Credits: AI Generated

DOI: 10.1186/s13062-026-01034-5

Keywords: DCAF13, hepatocellular carcinoma, RCAN1.4, ubiquitination, calcineurin, NFAT1, calcium signaling, E3 ubiquitin ligase, CRL4, biomarker, cancer biology, proteasomal degradation